



**Luciano Wannesson**

**Kontakt**

Luciano Wannesson

## Publikationen (9)

Passweg J, Baldomero H, Ansari M, Arber C, Chalandon Y, Daskalakis M, Diepold M, Diesch-Furlanetto T, Duchosal M, Gerull S, Güngör T, Heim D, Hitz F, Holbro A, Masouridi-Levrat S, Nair G, Novak U, Pabst T, Renner C, Stussi G, Schneidawind D, Schanz U, Wannesson L, Halter J, Swiss Blood Stem Cell Transplantation Group (SBST). Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997–2021. *Hematol Oncol* 2023

Schuler A, Huser J, Schmid S, Schär S, Scherz A, Gautschi O, Mauti L, von Briel T, Waibel C, Wannesson L, Pankovics J, Mark M, Rothschild S, Addeo A, Janthur W, Siano M, Boos L, Britschgi C, Früh M. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study. *Lung Cancer* 2023; 187:107427.

Mark M, Früh M, Biaggi-Rudolf C, Weindler S, Baudoux N, Schwitter M, Wannesson L, Jörgen M, Metaxas Y, Schneider M, Friedlaender A, Burmeister H, Janthur W, Rothschild S, Pless M, Addeo A, Eboulet E, Froesch P, Swiss Group for Clinical Cancer Research (SAKK). SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. *Cancer Immunol Immunother* 2020

Schmid S, Jochum W, Addeo A, Demmer I, Schär S, Janthur W, Wannesson L, König D, Britschgi C, Frösch P, Bouchaab H, Rothschild S, Blum V, Friedlaender A, Mauti L, Früh M. Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort. *Cancer Immunol Immunother* 2020; 69:1605–1613.

Ghilardi G, Ghielmini M, Wannesson L, Lerch E, Samaras P, Schanz U, Passweg J, Stussi G, Kleber M, Gerber B, Rossi D, Schmidt A, Pabst T, Jeker B, Müller R, Cairoli A, Müller A, Bargetzi M, Hitz F, Baldomero H, Heim D, Swiss Blood Stem Cell Transplantation Registry. Melphalan dose in myeloma patients  $\geq 65$  years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. *Bone Marrow Transplant* 2018

Baumgartner A, Mueller B, Stanga Z, Hess U, Duchosal M, Pabst T, Wannesson L, Limonta A, Pichard C, Chalandon Y, Samaras P, Schanz U, Passweg J, Medinger M, Zueger N, Bargetzi A, Bargetzi M, Schuetz P. Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison. *Nutrition* 2016; 35:43–50.

Papazoglou D, Stenner F, Kühne R, Baumann S, Richner J, Schmid M, von Burg P, von Rohr L, Nussbaum C, Mingrone W, Barth A, Winterhalder R, Hasler L, Rothermundt C, Gillessen Sommer S, Cathomas R, Berthold D, Wannesson L, Rothschild S. Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program. *Clin Genitourin Cancer* 2016

Gautschi O, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Huret B, Curioni-Fontecedro A, Milia J, Cabarro B, Bluthgen M, Besse B, Smit E, Wolf J, Peters S, Früh M, Koeberle D, Oulkhovir Y, Schuler M, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. *J Thorac Oncol* 2015; 10:1451–7.

Wannesson L, Samaras P, Renner C, Pabst T, Lerch E, Hess U, Heim D, Cerutti A, Cairoli A, Bargetzi M, Zucca E. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). *Leuk Lymphoma* 2012; 54:36–40.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)